Literature DB >> 28986884

The Role of CD44 and Cancer Stem Cells.

Liang Wang1, Xiangsheng Zuo2, Keping Xie1, Daoyan Wei3.   

Abstract

Solid tumors are composed of mutually interacting cancer cells and tumor microenvironment. Many environmental components, such as extracellular matrix (ECM), mesenchymal stem cells, endothelial and immune cells, and various growth factors and cytokines, provide signals, either stimulatory or inhibitory, to cancer cells and determine their fates. Meanwhile, cancer cells can also educate surrounding cells or tissues to undergo changes that are in favorable of tumor progression. CD44, as a transmembrane receptor for hyaluronic acid (HA) and many other ECM components and a coreceptor for growth factors and cytokines, is a critical cell surface molecule that can sense, integrate, and transduce cellular microenvironmental signals to membrane-associated cytoskeletal proteins or to cell nucleus to regulate a variety of gene expressions that govern cell behaviors. Mounting evidence suggests that CD44, particularly CD44v isoforms, are cancer stem cell (CSC) markers and critical regulators of cancer stemness, including self-renewal, tumor initiation, and metastasis. Thus, CD44 is widely used alone or in combination with other cell surface markers to isolate or enrich CSCs through fluorescence-activated cell sorting of dissociated single cells that originate from the patient, xenograft tumor tissues, or tumor cell cultures. Sorted cells are cultured in a specialized culture medium for spheroid formation or inoculated into immunodeficient mice for the analysis of tumorigenic or metastatic potential. In this chapter, detailed experimental methods regarding CD44+ tumor cell isolation, spheroid culture, and characterization will be described.

Entities:  

Keywords:  Biomarker; CD44; Cancer stem cell; Cell sorting; Methods; Splicing variants; Therapeutic target; Tumor microenvironment; Tumor spheroid

Mesh:

Substances:

Year:  2018        PMID: 28986884     DOI: 10.1007/978-1-4939-7401-6_3

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  52 in total

1.  Anti-EGFR treatment effects on laryngeal cancer stem cells.

Authors:  Glaucia Maria de Mendonça Fernandes; Ana Lívia Silva Galbiatti-Dias; Leticia Antunes Muniz Ferreira; Vilson Serafim Junior; Gabriela Helena Rodrigues-Fleming; Juliana Garcia de Oliveira-Cucolo; Patrícia Matos Biselli-Chicote; Rosa Sayoko Kawasaki-Oyama; José Victor Maniglia; Érika Cristina Pavarino; Eny Maria Goloni-Bertollo
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

Review 2.  Cancer stem cells in colorectal cancer and the association with chemotherapy resistance.

Authors:  Xue Lei; Qinglian He; Ziqi Li; Qian Zou; Pingrong Xu; Haibing Yu; Yuanlin Ding; Wei Zhu
Journal:  Med Oncol       Date:  2021-03-18       Impact factor: 3.064

Review 3.  Breaking the niche: multidimensional nanotherapeutics for tumor microenvironment modulation.

Authors:  K Laxmi Swetha; Kavya Sree Maravajjala; Shyh-Dar Li; Manu Smriti Singh; Aniruddha Roy
Journal:  Drug Deliv Transl Res       Date:  2022-06-13       Impact factor: 4.617

4.  TYMS-TM4SF4 axis promotes the progression of colorectal cancer by EMT and upregulating stem cell marker.

Authors:  Fen Zhang; Jiecheng Ye; Wenjing Guo; Fenfen Zhang; Liyuan Wang; Anjia Han
Journal:  Am J Cancer Res       Date:  2022-03-15       Impact factor: 6.166

5.  Treatment effects of the EGFR pathway drugs on head and neck cancer stem cells.

Authors:  Glaucia Maria de Mendonça Fernandes; Vilson Serafim Junior; Ana Lívia Silva Galbiatti-Dias; Leticia Antunes Muniz Ferreira; Márcia Maria Urbanin Castanhole-Nunes; Rosa Sayoko Kawasaki-Oyama; José Victor Maniglia; Erika Cristina Pavarino; Eny Maria Goloni-Bertollo
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

6.  A Novel Splice Variant of HYAL-4 Drives Malignant Transformation and Predicts Outcome in Patients with Bladder Cancer.

Authors:  Vinata B Lokeshwar; Daley S Morera; Sarrah L Hasanali; Travis J Yates; Marie C Hupe; Judith Knapp; Soum D Lokeshwar; Jiaojiao Wang; Martin J P Hennig; Rohitha Baskar; Diogo O Escudero; Ronny R Racine; Neetika Dhir; Andre R Jordan; Kelly Hoye; Ijeoma Azih; Murugesan Manoharan; Zachary Klaassen; Sravan Kavuri; Luis E Lopez; Santu Ghosh; Bal L Lokeshwar
Journal:  Clin Cancer Res       Date:  2020-02-24       Impact factor: 12.531

Review 7.  p63-related signaling at a glance.

Authors:  Matthew L Fisher; Seamus Balinth; Alea A Mills
Journal:  J Cell Sci       Date:  2020-09-11       Impact factor: 5.285

Review 8.  Clinical Relevance of Mesenchymal- and Stem-Associated Phenotypes in Circulating Tumor Cells Isolated from Lung Cancer Patients.

Authors:  Evangelia Pantazaka; Vasileios Vardas; Argyro Roumeliotou; Stavros Kakavogiannis; Galatea Kallergi
Journal:  Cancers (Basel)       Date:  2021-04-29       Impact factor: 6.639

9.  NUMB suppression by miR-9-5P enhances CD44+ prostate cancer stem cell growth and metastasis.

Authors:  Xuan Wang; Jun Cai; Lei Zhao; Dejun Zhang; Guojie Xu; Jianli Hu; Tao Zhang; Min Jin
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

10.  Relevance of circulating hybrid cells as a non-invasive biomarker for myriad solid tumors.

Authors:  Matthew S Dietz; Thomas L Sutton; Brett S Walker; Charles E Gast; Luai Zarour; Sidharth K Sengupta; John R Swain; Jennifer Eng; Michael Parappilly; Kristen Limbach; Ariana Sattler; Erik Burlingame; Yuki Chin; Austin Gower; Jose L Montoya Mira; Ajay Sapre; Yu-Jui Chiu; Daniel R Clayburgh; SuEllen J Pommier; Jeremy P Cetnar; Jared M Fischer; Jerry J Jaboin; Rodney F Pommier; Brett C Sheppard; V Liana Tsikitis; Alison H Skalet; Skye C Mayo; Charles D Lopez; Joe W Gray; Gordon B Mills; Zahi Mitri; Young Hwan Chang; Koei Chin; Melissa H Wong
Journal:  Sci Rep       Date:  2021-07-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.